Compare TNET & CLDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TNET | CLDX |
|---|---|---|
| Founded | 1988 | N/A |
| Country | United States | United States |
| Employees | 2700 | N/A |
| Industry | Business Services | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 2.6B |
| IPO Year | 2000 | 1995 |
| Metric | TNET | CLDX |
|---|---|---|
| Price | $66.72 | $41.36 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | ★ $65.80 | $46.60 |
| AVG Volume (30 Days) | 385.0K | ★ 942.8K |
| Earning Date | 04-30-2026 | 05-04-2026 |
| Dividend Yield | ★ 2.57% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 3.05 | N/A |
| Revenue | ★ $5,010,000,000.00 | $12,743,000.00 |
| Revenue This Year | N/A | $111.39 |
| Revenue Next Year | $3.30 | $235.85 |
| P/E Ratio | $22.42 | ★ N/A |
| Revenue Growth | N/A | ★ 87.78 |
| 52 Week Low | $33.67 | $19.72 |
| 52 Week High | $73.08 | $41.15 |
| Indicator | TNET | CLDX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Trinet Group Inc provides human resources solutions for small and medium-sized businesses through technology-enabled services. Its offerings include human capital expertise, employee benefits such as health insurance and retirement plans, payroll and payroll tax administration, risk mitigation, and compliance consulting. The company provides its services through professional employer organization (PEO) services delivered via a co-employment model, as well as administrative services organization (ASO) offerings. The majority of the company's revenue is derived from the insurance-related billings and administrative fees collected from PEO clients.
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.